Does the media refer more to GKOS or GEHC?

In the previous week, GE HealthCare Technologies had 7 more articles in the media than Glaukos. MarketBeat recorded 16 mentions for GE HealthCare Technologies and 9 mentions for Glaukos. GE HealthCare Technologies' average media sentiment score of 0.63 beat Glaukos' score of 0.44 indicating that GE HealthCare Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 3 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GE HealthCare Technologies 6 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, RMD or GKOS?

ResMed has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ResMed $5.65B 5.82 $1.52B $10.98 21.30 Glaukos $507.44M 27.63 -$187.69M -$2.94 N/A

Is RMD or GKOS more profitable?

ResMed has a net margin of 27.79% compared to Glaukos' net margin of -24.60%. ResMed's return on equity of 26.42% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets ResMed 27.79% 26.42% 19.43% Glaukos -24.60% -0.97% -0.71%

Does the media prefer RMD or GKOS?

In the previous week, Glaukos had 1 more articles in the media than ResMed. MarketBeat recorded 9 mentions for Glaukos and 8 mentions for ResMed. ResMed's average media sentiment score of 0.54 beat Glaukos' score of 0.44 indicating that ResMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ResMed 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Glaukos 3 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, DXCM or GKOS?

DexCom has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DexCom $4.66B 6.39 $836.30M $2.55 31.34 Glaukos $507.44M 27.63 -$187.69M -$2.94 N/A

Is DXCM or GKOS more profitable?

DexCom has a net margin of 19.42% compared to Glaukos' net margin of -24.60%. DexCom's return on equity of 37.77% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets DexCom 19.42% 37.77% 15.98% Glaukos -24.60% -0.97% -0.71%

Does the media refer more to DXCM or GKOS?

In the previous week, Glaukos had 3 more articles in the media than DexCom. MarketBeat recorded 9 mentions for Glaukos and 6 mentions for DexCom. DexCom's average media sentiment score of 1.03 beat Glaukos' score of 0.44 indicating that DexCom is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Glaukos 3 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer PHG or GKOS?

Glaukos has a consensus price target of $216.71, indicating a potential downside of 8.49%. Given Glaukos' stronger consensus rating and higher possible upside, analysts plainly believe Glaukos is more favorable than Koninklijke Philips. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Koninklijke Philips 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Glaukos 1 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.88

Which has higher earnings & valuation, PHG or GKOS?

Koninklijke Philips has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Koninklijke Philips, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Koninklijke Philips $20.17B 1.48 $1.01B $1.17 25.96 Glaukos $507.44M 27.63 -$187.69M -$2.94 N/A

Does the media refer more to PHG or GKOS?

In the previous week, Glaukos had 4 more articles in the media than Koninklijke Philips. MarketBeat recorded 9 mentions for Glaukos and 5 mentions for Koninklijke Philips. Koninklijke Philips' average media sentiment score of 0.66 beat Glaukos' score of 0.44 indicating that Koninklijke Philips is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Koninklijke Philips 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Glaukos 3 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, GKOS or STE?

STERIS has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $507.44M 27.63 -$187.69M -$2.94 N/A STERIS $5.94B 4.21 $782.30M $8.43 30.51

Is GKOS or STE more profitable?

STERIS has a net margin of 13.41% compared to Glaukos' net margin of -24.60%. STERIS's return on equity of 14.80% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets Glaukos -24.60% -0.97% -0.71% STERIS 13.41% 14.80% 9.99%

Does the media favor GKOS or STE?

In the previous week, STERIS had 8 more articles in the media than Glaukos. MarketBeat recorded 17 mentions for STERIS and 9 mentions for Glaukos. STERIS's average media sentiment score of 1.09 beat Glaukos' score of 0.44 indicating that STERIS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 3 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral STERIS 9 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Glaukos (GKOS) Competitors

$246.09 +9.90 (+4.19%)

As of 01:09 PM Eastern

Compare

GKOS vs. GEHC, RMD, DXCM, PHG, and STE

Should you buy Glaukos stock or one of its competitors? Glaukos's main competitors and comparable companies include GE HealthCare Technologies (GEHC), ResMed (RMD), DexCom (DXCM), Koninklijke Philips (PHG), and STERIS (STE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Glaukos compare to GE HealthCare Technologies?

Glaukos (NYSE:GKOS) and GE HealthCare Technologies (NASDAQ:GEHC) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

GE HealthCare Technologies has a net margin of 9.96% compared to Glaukos' net margin of -24.60%. GE HealthCare Technologies' return on equity of 20.45% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-24.60%	-0.97%	-0.71%
GE HealthCare Technologies	9.96%	20.45%	5.97%

99.0% of Glaukos shares are held by institutional investors. Comparatively, 82.1% of GE HealthCare Technologies shares are held by institutional investors. 5.9% of Glaukos shares are held by insiders. Comparatively, 0.4% of GE HealthCare Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

GE HealthCare Technologies has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than GE HealthCare Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	27.63	-$187.69M	-$2.94	N/A
GE HealthCare Technologies	$20.63B	1.83	$2.08B	$4.74	17.65

In the previous week, GE HealthCare Technologies had 7 more articles in the media than Glaukos. MarketBeat recorded 16 mentions for GE HealthCare Technologies and 9 mentions for Glaukos. GE HealthCare Technologies' average media sentiment score of 0.63 beat Glaukos' score of 0.44 indicating that GE HealthCare Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	3 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GE HealthCare Technologies	6 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Glaukos currently has a consensus target price of $216.71, suggesting a potential downside of 8.49%. GE HealthCare Technologies has a consensus target price of $80.87, suggesting a potential downside of 3.32%. Given GE HealthCare Technologies' higher probable upside, analysts clearly believe GE HealthCare Technologies is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
GE HealthCare Technologies	0 Sell rating(s)	11 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.52

Glaukos has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, GE HealthCare Technologies has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market.

Summary

GE HealthCare Technologies beats Glaukos on 10 of the 17 factors compared between the two stocks.

How does Glaukos compare to ResMed?

ResMed (NYSE:RMD) and Glaukos (NYSE:GKOS) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

55.0% of ResMed shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 0.6% of ResMed shares are held by company insiders. Comparatively, 5.9% of Glaukos shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

ResMed has a net margin of 27.79% compared to Glaukos' net margin of -24.60%. ResMed's return on equity of 26.42% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ResMed	27.79%	26.42%	19.43%
Glaukos	-24.60%	-0.97%	-0.71%

ResMed currently has a consensus price target of $253.69, suggesting a potential upside of 8.48%. Glaukos has a consensus price target of $216.71, suggesting a potential downside of 8.49%. Given ResMed's higher possible upside, equities analysts plainly believe ResMed is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ResMed	0 Sell rating(s)	11 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.39
Glaukos	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

ResMed has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, Glaukos has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

ResMed has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ResMed	$5.65B	5.82	$1.52B	$10.98	21.30
Glaukos	$507.44M	27.63	-$187.69M	-$2.94	N/A

In the previous week, Glaukos had 1 more articles in the media than ResMed. MarketBeat recorded 9 mentions for Glaukos and 8 mentions for ResMed. ResMed's average media sentiment score of 0.54 beat Glaukos' score of 0.44 indicating that ResMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ResMed	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Glaukos	3 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ResMed beats Glaukos on 10 of the 17 factors compared between the two stocks.

How does Glaukos compare to DexCom?

DexCom (NASDAQ:DXCM) and Glaukos (NYSE:GKOS) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

In the previous week, Glaukos had 3 more articles in the media than DexCom. MarketBeat recorded 9 mentions for Glaukos and 6 mentions for DexCom. DexCom's average media sentiment score of 1.03 beat Glaukos' score of 0.44 indicating that DexCom is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Glaukos	3 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

DexCom presently has a consensus target price of $95.50, suggesting a potential upside of 19.49%. Glaukos has a consensus target price of $216.71, suggesting a potential downside of 8.49%. Given DexCom's stronger consensus rating and higher possible upside, equities analysts plainly believe DexCom is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	0 Sell rating(s)	2 Hold rating(s)	24 Buy rating(s)	2 Strong Buy rating(s)	3.00
Glaukos	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

DexCom has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market. Comparatively, Glaukos has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

DexCom has a net margin of 19.42% compared to Glaukos' net margin of -24.60%. DexCom's return on equity of 37.77% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	19.42%	37.77%	15.98%
Glaukos	-24.60%	-0.97%	-0.71%

DexCom has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.66B	6.39	$836.30M	$2.55	31.34
Glaukos	$507.44M	27.63	-$187.69M	-$2.94	N/A

97.8% of DexCom shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 0.3% of DexCom shares are held by insiders. Comparatively, 5.9% of Glaukos shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

DexCom beats Glaukos on 13 of the 17 factors compared between the two stocks.

How does Glaukos compare to Koninklijke Philips?

Koninklijke Philips (NYSE:PHG) and Glaukos (NYSE:GKOS) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Koninklijke Philips has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Koninklijke Philips, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Koninklijke Philips	$20.17B	1.48	$1.01B	$1.17	25.96
Glaukos	$507.44M	27.63	-$187.69M	-$2.94	N/A

Koninklijke Philips has a net margin of 5.40% compared to Glaukos' net margin of -24.60%. Koninklijke Philips' return on equity of 14.86% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Koninklijke Philips	5.40%	14.86%	6.20%
Glaukos	-24.60%	-0.97%	-0.71%

13.7% of Koninklijke Philips shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 5.9% of Glaukos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Koninklijke Philips has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Glaukos has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

Glaukos has a consensus price target of $216.71, indicating a potential downside of 8.49%. Given Glaukos' stronger consensus rating and higher possible upside, analysts plainly believe Glaukos is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Koninklijke Philips	0 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Glaukos	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Glaukos had 4 more articles in the media than Koninklijke Philips. MarketBeat recorded 9 mentions for Glaukos and 5 mentions for Koninklijke Philips. Koninklijke Philips' average media sentiment score of 0.66 beat Glaukos' score of 0.44 indicating that Koninklijke Philips is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Koninklijke Philips	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Glaukos	3 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Koninklijke Philips beats Glaukos on 9 of the 17 factors compared between the two stocks.

How does Glaukos compare to STERIS?

Glaukos (NYSE:GKOS) and STERIS (NYSE:STE) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

STERIS has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	27.63	-$187.69M	-$2.94	N/A
STERIS	$5.94B	4.21	$782.30M	$8.43	30.51

In the previous week, STERIS had 8 more articles in the media than Glaukos. MarketBeat recorded 17 mentions for STERIS and 9 mentions for Glaukos. STERIS's average media sentiment score of 1.09 beat Glaukos' score of 0.44 indicating that STERIS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	3 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
STERIS	9 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.0% of Glaukos shares are owned by institutional investors. Comparatively, 94.7% of STERIS shares are owned by institutional investors. 5.9% of Glaukos shares are owned by company insiders. Comparatively, 1.1% of STERIS shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Glaukos currently has a consensus target price of $216.71, indicating a potential downside of 8.49%. STERIS has a consensus target price of $276.33, indicating a potential upside of 7.43%. Given STERIS's higher probable upside, analysts plainly believe STERIS is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

STERIS has a net margin of 13.41% compared to Glaukos' net margin of -24.60%. STERIS's return on equity of 14.80% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-24.60%	-0.97%	-0.71%
STERIS	13.41%	14.80%	9.99%

Glaukos has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, STERIS has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market.

Summary

STERIS beats Glaukos on 11 of the 17 factors compared between the two stocks.

Get Glaukos News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GKOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GKOS vs. The Competition

Export

Metric	Glaukos	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$14.54B	$6.03B	$7.87B	$23.59B
Dividend Yield	N/A	1.69%	2.47%	3.73%
P/E Ratio	-83.56	38.93	34.20	30.44
Price / Sales	28.71	5.45	8.50	3.41
Price / Cash	N/A	24.25	22.22	15.97
Price / Book	20.30	4.32	4.44	3.77
Net Income	-$187.69M	$142.48M	$3.50B	$1.08B
7 Day Performance	-0.77%	-1.81%	-0.81%	-0.51%
1 Month Performance	48.82%	-0.84%	-3.95%	1.14%
1 Year Performance	173.83%	-0.94%	1.61%	6.83%

Glaukos Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GKOS Glaukos	2.5837 of 5 stars	$246.09 +4.2%	$216.71 -11.9%	+168.4%	$14.54B	$507.44M	N/A	1,094
GEHC GE HealthCare Technologies	3.6587 of 5 stars	$79.55 +3.9%	$80.57 +1.3%	+13.8%	$35.97B	$21.64B	16.78	54,000	Analyst Forecast
RMD ResMed	4.2929 of 5 stars	$232.98 +1.3%	$253.69 +8.9%	-6.5%	$35.18B	$5.65B	21.22	11,370
DXCM DexCom	3.928 of 5 stars	$84.76 +3.0%	$95.50 +12.7%	+45.7%	$31.05B	$5.10B	33.24	11,000
PHG Koninklijke Philips	2.9094 of 5 stars	$27.57 +2.4%	N/A	+7.4%	$27.12B	$17.67B	20.31	65,340

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:GKOS) was last updated on 11/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Glaukos (GKOS) Competitors

GKOS vs. GEHC, RMD, DXCM, PHG, and STE

How does Glaukos compare to GE HealthCare Technologies?

Summary

How does Glaukos compare to ResMed?

Summary

How does Glaukos compare to DexCom?

Summary

How does Glaukos compare to Koninklijke Philips?

Summary

How does Glaukos compare to STERIS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GKOS vs. The Competition

Glaukos Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Glaukos (GKOS) Competitors

GKOS vs. GEHC, RMD, DXCM, PHG, and STE

How does Glaukos compare to GE HealthCare Technologies?

Is GKOS or GEHC more profitable?

Do institutionals and insiders hold more shares of GKOS or GEHC?

Which has preferable valuation and earnings, GKOS or GEHC?

Does the media refer more to GKOS or GEHC?

Do analysts recommend GKOS or GEHC?

Which has more volatility & risk, GKOS or GEHC?

Summary

How does Glaukos compare to ResMed?

Do institutionals and insiders have more ownership in RMD or GKOS?

Is RMD or GKOS more profitable?

Do analysts rate RMD or GKOS?

Which has more volatility and risk, RMD or GKOS?

Which has preferable earnings and valuation, RMD or GKOS?

Does the media prefer RMD or GKOS?

Summary

How does Glaukos compare to DexCom?

Does the media refer more to DXCM or GKOS?

Do analysts rate DXCM or GKOS?

Which has more risk and volatility, DXCM or GKOS?

Is DXCM or GKOS more profitable?

Which has stronger earnings and valuation, DXCM or GKOS?

Do institutionals and insiders hold more shares of DXCM or GKOS?

Summary

How does Glaukos compare to Koninklijke Philips?

Which has higher earnings & valuation, PHG or GKOS?

Is PHG or GKOS more profitable?

Do institutionals and insiders believe in PHG or GKOS?

Which has more risk & volatility, PHG or GKOS?

Do analysts prefer PHG or GKOS?

Does the media refer more to PHG or GKOS?

Summary

How does Glaukos compare to STERIS?

Which has better valuation & earnings, GKOS or STE?

Does the media favor GKOS or STE?

Do institutionals & insiders hold more shares of GKOS or STE?

Do analysts rate GKOS or STE?

Is GKOS or STE more profitable?

Which has more risk and volatility, GKOS or STE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GKOS vs. The Competition

Glaukos Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools